I can see why you are a little confused after ATH announced they had opened enrollment in NZ for the phase2 clinical trial. Now this 1 year preclinical. Raises the question of how other P3 NSA end points for trials currently in progress in the US have identified. On June 2 the headline very clearly was the phase2 had been launched. ATH need to clarity IMO. I can understand how an investor who bought in on the June 2 announcement could be a little peeved if the trial has now been set back a year,
A biomuse natural history study has already been completed and data presented.
Ann: Meeting with US FDA provides development path for ATH434, page-11
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $4.579K | 1.526M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 749591 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 133062022 | 26 |
View Market Depth
| Last trade - 14.03pm 13/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |